Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

House Committee Watching Genasense; Show Of Force During FDA Review

May 10 2004

• By The Pink Sheet

Related Content

Gleevec Indigent Patient Program Will Continue After Medicare Rx

Mar 22 2004

Hemispherx Ampligen NDA Plans Could Pose Challenge For FDA

Mar 08 2004

Genasense Progression-Free Survival Data Do Not Show “Real Effect,” Cmte.

May 10 2004

Bristol UFT/Leucovorin Approval May Await Analysis Of Uracil Contribution

Sep 20 1999

Bristol-Myers Squibb UFT

Apr 02 2001

FDA CONFIDENTIALITY CONCERNS PRECLUDE RESPONSES TO INDIVIDUAL PATIENT COMPLAINTS ABOUT DIFFICULTIES RECEIVING UNAPPROVED MEDICATIONS, HHS MAINTAINS

Sep 29 1997

More from Archive

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window